Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.


Por: Bourhis J, Aupérin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R and Tao Y

Publicada: 24 ene 2026 Ahead of Print: 22 dic 2025
Resumen:
BACKGROUND: Postoperative cisplatin and radiotherapy is the standard of care for high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The NIVOPOST-OP trial aimed to assess the efficacy and safety of programmed death 1 blockade by nivolumab added to cisplatin and radiotherapy in this setting. METHODS: This open-label, phase 3 trial evaluated adding nivolumab to cisplatin and radiotherapy after surgery for LA-SCCHN with high-risk pathological features. The main inclusion criteria were age 19-74 years, an Eastern Cooperative Oncology Group performance status 0-1, squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx resected with macroscopic complete resection, and at least one high-risk pathological feature: nodal extracapsular extension, microscopically positive margins, four or more cervical nodal involvements without extracapsular extension, and multiple perineural invasions. 680 participants recruited in 82 sites across six countries (France, Spain, Poland, Belgium, Greece, and Switzerland) were randomly assigned 1:1 to receive cisplatin and radiotherapy (66 Gy, cisplatin 100 mg/m(2) intravenously once every 3 weeks, for three cycles); or nivolumab 240 mg intravenously, followed by cisplatin and radiotherapy with three cycles of concomitant nivolumab 360 mg once every 3 weeks, and six cycles of adjuvant nivolumab 480 mg once every 4 weeks. The primary endpoint was disease-free survival as per investigator assessment in the intention-to-treat population. 230 disease-free survival events (relapses or deaths) were required to detect a hazard ratio of 0·65 with 0·05 two-sided a error, with 90% power. The trial is registered at ClinicalTrials.gov (NCT03576417) and is active, but not recruiting. FINDINGS: The 680 patients were recruited from Oct 15, 2018, to July 3, 2024. The analysis was based on 666 participants randomly assigned until the cutoff date (April 30, 2024), at which point the required number of events was reached (median follow-up 30·3 months). Disease-free survival was significantly improved with nivolumab, cisplatin, and radiotherapy versus cisplatin and radiotherapy alone, irrespective of programmed death ligand 1 expression (HR 0·76; 95% CI 0·60-0·98; stratified log-rank test p value=0·034). There was an increase in the rate of participants with treatment-related grade 4 adverse events with nivolumab, cisplatin, and radiotherapy compared with cisplatin and radiotherapy (30 [10%] of 312 vs 16 [5%] of 306). Treatment-related deaths occurred in two participants in each group. INTERPRETATION: Nivolumab added to cisplatin and radiotherapy in high-risk resected LA-SCCHN improves disease-free survival with moderate toxic effect increase, and can be proposed as a new standard treatment. FUNDING: Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC) and Bristol Myers Squibb.

Filiaciones:
Bourhis J:
 Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Aupérin A:
 Biostatistics and Epidemiology Office, Gustave Roussy, Inserm U1018 Oncostat labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France

Borel C:
 Institut De Cancérologie Strasbourg Europe, Strasbourg, France

Lefebvre G:
 Centre Oscar Lambret, Lille, France

Racadot S:
 Centre Leon Bérard, Lyon, France

Geoffrois L:
 Institut de Cancérologie de Lorraine, Vandoeuvre-Lés-Nancy, France

Sun XS:
 Hopital Nord Franche Comté, Montbelliard, France

Saada E:
 Centre Antoine Lacassagne, Nice, France

Cirauqui B:
 Institut Català d'Oncologia Badalona, Barcelona, Spain

Rutkowski T:
 Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland

Henry S:
 Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Namur Site Sainte Elisabeth, Namur, Belgium

Modesto A:
 Claudius Regaud Institute, Toulouse, France

Johnson A:
 Centre François Baclesse, Caen, France

Chapet S:
 CHRU Bretonneau, Tours France

Calderon B:
 Institut Sainte Catherine, Avignon, France

Sire C:
 Centre Hospitalier de Bretagne Sud, Lorient, France

Malard O:
 Centre Hospitalier Universitaire de Nantes, Nantes, France

Bainaud M:
 Centre Hospitalier Universitaire Poitiers, Poitiers, France

Da Silva Motta A:
 Institut de Cancérologie Jean Godinot, Reims, France

Thureau S:
 Centre Henri Becquerel, Rouen, France

Pointreau Y:
 Clinique Victor Hugo-Centre Jean Bernard, Le Mans, France

Blanchard P:
 Gustave Roussy, Villejuif, France

Buiret G:
 Centre Hospitalier de Valence, Valence, France

Bozec L:
 Institut Curie-Hopital René Huguenin, Saint Cloud, France

Lopez S:
 Centre Hospitalier Annecy Genevois, Pringy, France

Vanbockstael J:
 Institut de Cancérologie de l'Ouest René Gauducheau, Saint Herblain, France

Bosset M:
 Centre Marie Curie-Hôpital Privé Drôme Ardèche, Valence, France

Greilsamer C:
 Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France

Daste A:
 Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Bruna A:
 Hôpital Privé Sainte Marie, Chalon sur Saone, France

N'Guyen F:
 Gustave Roussy, Villejuif, France

Plana M:
 Institut Català d'Oncologia, Barcelona, Spain

Iruarrizaga E:
 Hospital Universitario de Cruces, Barakaldo, Spain

Temam S:
 Gustave Roussy, Villejuif, France

Even C:
 Gustave Roussy, Villejuif, France

Ruiz EP:
 Hospital Regional Universitario de Málaga, Malaga, Spain

Bert M:
 GORTEC, Radiotherapy Oncology Group for Head and Neck, Tours, France

Karamouza E:
 Biostatistics and Epidemiology Office, Gustave Roussy, Inserm U1018 Oncostat labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France

Thariat J:
 Centre François Baclesse, Caen, France

Kazmierska J:
 Gielkopolskie Centrun Onkologii im Marii Curie-Sklodowskiej Greater Poland Cancer Center, Poznan, Poland

Psyrri A:
 Medical Oncology, Attikon University Hospital, Athens, Greece

:
 Institut Català d'Oncologia, Institut de Recerca Germans Trias i Pujol, Badalona, Spain

Tao Y:
 Department of Radiation Oncology and INSERM, U1030 Molecular Radiotherapy and Therapeutic Innovations, Gustave Roussy, Villejuif, France
ISSN: 01406736





LANCET
Editorial
The Lancet Publishing Group, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Reino Unido
Tipo de documento: Article
Volumen: 407 Número: 10526
Páginas: 363-374
WOS Id: 001679308800007
ID de PubMed: 41448222

MÉTRICAS